#United Arab Emirates #Dubai #Viatris #Inpefa #Sotagliflozin

Viatris Expands Its Cardiovascular Portfolio with Inpefa® in the UAE

Viatris Inc., a global leader in healthcare solutions, has taken a significant stride in treating cardiovascular diseases by launching Inpefa® (sotagliflozin) in the United Arab Emirates (UAE). This launching event not only marks the entry of Inpefa in the UAE but also establishes it as the first country within Viatris’s territories to commercialize this revolutionary treatment

Inpefa is notable for being the first and only dual SGLT1/2 inhibitor approved specifically for heart failure treatment. The launch symbolizes the company's commitment to enhancing access to healthcare solutions in key markets outside the U.S. and Europe. With plans to introduce Inpefa in other countries over the next few years, Viatris aims to bring this crucial treatment to more patients globally.

The Importance of Inpefa® in Heart Failure Treatment

Heart failure is recognized as the leading cause of hospitalization worldwide, affecting over 64 million people. The condition arises when the heart's ability to pump blood efficiently is compromised, leading to insufficient blood and oxygen reaching vital tissues. The introduction of Inpefa responds to the critical and growing need for innovative therapies that can effectively address this burgeoning health crisis.

How Inpefa Works

Sotagliflozin, the active ingredient in Inpefa, functions by inhibiting two sodium-glucose cotransporters—SGLT1 and SGLT2. These proteins play a significant role in glucose regulation, with SGLT2 primarily involved in glucose reabsorption in the kidneys, while SGLT1 affects glucose absorption in the small intestine and the heart. By targeting both pathways, Inpefa offers a multifaceted approach that may enhance patient outcomes in managing heart failure, particularly among those with coexisting conditions such as type 2 diabetes and chronic kidney disease.

Approval in the UAE follows positive outcomes from pivotal Phase 3 clinical trials, including the SOLOIST-WHF and SCORED studies. These trials enrolled more than 11,800 patients and demonstrated that Inpefa significantly reduced major cardiovascular events, illustrating its potential benefit in both heart failure and diabetic populations. In fact, results showed a 33% reduction in heart failure-related hospitalizations and a substantial reduction in cardiovascular death and adverse outcomes associated with heart failure.

Future Prospects for Inpefa

Viatris continues to expand the reach of Inpefa, having submitted regulatory filings in countries such as Canada, Australia, and Mexico. The company views this expansion as a vital aspect of its strategy to diversify its innovative portfolio and utilize its robust pipeline to bring groundbreaking treatments to market.

Corinne Le Goff, Chief Commercial Officer at Viatris, stated, "The launch of Inpefa in the UAE marks another important step as we continue to deliver innovative medicines for patients around the world." This sentiment resonates strongly, considering the pressing need for new therapeutic options to manage the burden of heart failure effectively. With health authorities and medical professionals keenly observing the progress of Inpefa, the anticipation is high for the treatment's performance in the broader healthcare landscape.

As Viatris moves forward in its mission to empower patients around the globe, the promising prospects around Inpefa stand as a testament to the company's dedication to addressing critical health needs. The goal is clear: expand access to innovative treatments that can enhance quality of life and reduce the burden of chronic diseases on healthcare systems.

About Viatris

Viatris, which operates under the Nasdaq listing VTRS, is committed to bridging the traditional divide between generics and brand-name drugs. With a focus on integrating the best of both worlds, the organization aims to improve health outcomes globally. By providing high-quality medicines to nearly one billion patients annually, Viatris tackles various health challenges at all stages of life. The company's commitment to innovation in cardiovascular health, epitomized by the Inpefa launch, emphasizes its mission to foster a healthier world.

Unlocking the potential of treatments like Inpefa can significantly impact the future of healthcare, especially in the realm of cardiovascular diseases, which continue to escalate worldwide.